UGCG
Ceramide glucosyltransferase
As of the edition of 20 October 2026, UGCG (ceramide glucosyltransferase, UniProt Q16739) has 4 drugs tested at it and 5 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q16739
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 8
- Disease areas
- Inherited and neonatal; Nervous system; Nutrition and metabolism; Heart and blood vessels; Blood and lymph; Urinary and reproductive; Digestive system; Cancer
- Registered trials of its drugs
- 78
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Miglustat | Marketed | Phase 4 | none listed |
| Eliglustat | Marketed | Phase 3 | Ends 2030 |
| Venglustat | Active | Phase 3 | none listed |
| Lucerastat | Active | Phase 3 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Engaged | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Sanofi | Route B |
| Amicus Therapeutics | Route B |
| Johnson & Johnson | Route B |
The other 2 companies at UGCG
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at UGCG, ranked, with the facts behind eachRequest access. Nothing is shown until you do.